Company news
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news
Sangamo Therapeutics, Inc. news releases on 6ix. Latest, Nov 1, 2023: Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial…
Press releases — page 2
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
October 31, 2023
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 24, 2023
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 23, 2023
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
September 19, 2023
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 7, 2023
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
July 31, 2023
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 19, 2023
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
July 16, 2023
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
June 28, 2023
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 21, 2023
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 15, 2023
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 1, 2023
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
April 25, 2023
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
April 18, 2023
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
February 21, 2023
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
February 21, 2023
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 20, 2023
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
November 2, 2022
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
October 26, 2022
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
October 11, 2022
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
August 29, 2022
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 3, 2022
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
July 27, 2022
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
July 20, 2022
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
May 31, 2022
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 4, 2022
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 1, 2022
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
April 27, 2022
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
March 28, 2022
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
February 23, 2022
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
February 16, 2022
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
February 6, 2022
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
January 5, 2022
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
January 3, 2022
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
December 11, 2021
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
December 11, 2021
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
November 3, 2021
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
November 3, 2021
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
October 27, 2021
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
August 8, 2021
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 4, 2021
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
July 28, 2021
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
May 23, 2021
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
May 20, 2021
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 3, 2021
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
April 26, 2021
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
April 26, 2021
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
March 24, 2021
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
March 16, 2021
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
February 23, 2021